Adjuvant endocrine therapies such as tamoxifen, a selective estrogen receptor modulator, and aromatase inhibitors (AIs) such as anastrozole, letrozole, or exemestane are often administered as maintenance therapy to individuals with breast cancer who have completed curative treatment [3]. Here, CYP19A1 is linked to breast carcinoma.